MAP4

Microtubule-associated protein 4 · P27816 · MAP4 on Sugi Atlas →

0 patent compounds predicted against MAP4, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to MAP4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) PHASE2/PHASE3ACTIVE_NOT_RECRUITING
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer PHASE3COMPLETED
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) PHASE1/PHASE2NOT_YET_RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations PHASE2COMPLETED
Memantine Therapy in Amyotrophic Lateral Sclerosis PHASE2COMPLETED
A Multicenter Study of NAP (AL-108) in Schizophrenia PHASE2COMPLETED
A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age PHASE2ACTIVE_NOT_RECRUITING
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia PHASE1UNKNOWN
Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. PHASE1COMPLETED
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia PHASE1COMPLETED
Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults PHASE1COMPLETED
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) PHASE1RECRUITING
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Exploratory Evaluation of [11C]MPC6827 EARLY_PHASE1COMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers. nanRECRUITING
Evaluation of a Novel PET Radioligand to Image OGA nanCOMPLETED
Neurofilament Surveillance Project (NSP) nanACTIVE_NOT_RECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Efficacy of Cognitive Rehabilitation Using Virtual Reality and Computer-based Cognitive Stimulation on Cognitive Impairment Associated to Movement Disorders nanCOMPLETED
Susceptibility Genes in Autism Spectrum Disorders nanCOMPLETED
Importance of the Microtubule Cytoskeleton in Oocyte Competence nanCOMPLETED
Identification of New FTLD Genes nanUNKNOWN
Cognitive Neurology Unit Clinical Registry nanRECRUITING
Diagnostic of Chemotherapy Induced Neuropathy in Children nanCOMPLETED
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease nanUNKNOWN
Toward Molecular Profiling of Parkinson's Disease in Easily Accessible Biological Matrices nanACTIVE_NOT_RECRUITING
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease nanRECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAP4 binder may also engage these)

ProteinNameSimilarity
P36225 1.000 P36225 →
Q5M7W5 1.000 Q5M7W5 →
P27546 1.000 P27546 →
P19332 0.987 P19332 →
O54963 0.987 O54963 →
Q99P72 0.987 Q99P72 →
RTN4 Reticulon-4 0.987 landscape →
Q8VIG1 0.986 Q8VIG1 →
A4FU49 0.986 A4FU49 →
Q5S6V2 0.986 Q5S6V2 →
Q13127 0.986 Q13127 →
Q9VYD1 0.986 Q9VYD1 →
Q5YCW0 0.985 Q5YCW0 →
ASH1L Histone-lysine N-methyltransferase ASH1L 0.985 landscape →
Q5YCV9 0.985 Q5YCV9 →
MAPT Microtubule-associated protein tau 0.985 landscape →
Q9JK11 0.985 Q9JK11 →
Q99LM3 0.985 Q99LM3 →
Q5STT6 0.984 Q5STT6 →
Q8BZ32 0.983 Q8BZ32 →
Q95J40 0.983 Q95J40 →
Q5YCW1 0.983 Q5YCW1 →
A2AEY4 0.983 A2AEY4 →
Q28820 0.982 Q28820 →
P10637 0.982 P10637 →
Q9QX75 0.982 Q9QX75 →
Q13061 0.982 Q13061 →
P23226 0.981 P23226 →
A6NCI8 0.981 A6NCI8 →
MAP7D3 MAP7 domain-containing protein 3 0.981 landscape →